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a  b  s  t  r  a  c  t
Rheumatoid  arthritis  (RA)  is a chronic  inﬂammatory  disorder  that  primarily  involves  the  joints.  Accurate
and  frequent  assessment  of RA  disease  activity  is  critical  to optimal  treatment  planning.  A novel  algo-
rithm  has  been  developed  to determine  a  multi-biomarker  disease  activity  (MBDA)  score  based  upon
measurement  of the  concentrations  of  12  serum  biomarkers  in multiplex  format.  Biomarker  assays  from
several  different  platforms  were  used  in  feasibility  studies  to  identify  biomarkers  of potential  signiﬁ-
cance.  These  assays  were  adapted  to  a multiplex  platform  for training  and  validation  of the  algorithm.
In  this  study,  the  analytical  performance  of  the  underlying  biomarker  assays  and  the  MBDA  score  was
evaluated.  Quantiﬁcation  of 12  biomarkers  was  performed  with  multiplexed  sandwich  immunoassays
in  three  panels.  Biomarker-speciﬁc  capture  antibodies  were  bound  to speciﬁc  locations  in  each  well;
detection  antibodies  were  labeled  with  electrochemiluminescent  tags.  Data  were  acquired  with  a  Sector
Imager  6000,  and  analyte  concentrations  were  determined.  Parallelism,  dynamic  range,  cross-reactivity,
and  precision  were  established  for each  biomarker  as well  as  for  the  MBDA  score.  Interference  by  serum
proteins,  heterophilic  antibodies,  and  common  RA  therapies  was  also  assessed.  The  individual  biomarker
assays  had  3–4 orders  of  magnitude  dynamic  ranges,  with  good  reproducibility  across  time,  operators,
and  reagent  lots;  the  MBDA  score  had  a  median  coefﬁcient  of  variation  of  <2%  across  the  score  range.
Cross-reactivity  as  well  as  interference  by serum  rheumatoid  factor  (RF),  human  anti-mouse  antibodies
(HAMA),  or  common  RA  therapies,  including  disease-modifying  antirheumatic  drugs  and  biologics,  was
minimal.  The  same  MBDA  score  was observed  in different  subjects  despite  having  different  biomarker
 literaproﬁles,  supporting  prior
. Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inﬂammatory
isorder of unknown etiology that primarily affects the joints,
xhibiting local inﬂammation and cartilage destruction. The dis-
ase course can vary greatly among patients, from mild and
elf-limiting to severe. Similarly, response to therapeutic inter-
ention can vary greatly. A number of clinical parameters have
een developed for measuring RA disease activity [1–3]. Swollen
nd tender joints counts are the historical “gold standard” used to
ssess and monitor patients [4]. Joint counts alone, however, are
edious, time-consuming, poorly reproducible [5] and dependent
n the skill and interpretation of the examiner [6]. In an attempt
 Portions of these data were previously presented at the 2010 European league
gainst  rheumatism.
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Open access under CC BY-NC-ND license.ture  reports  that  multiple  pathways  contribute  to RA.
© 2012 Elsevier B.V. 
to provide an overall clinical picture that integrates the hetero-
geneous manifestations of RA, indices have been developed that
combine multiple measures into composite scores reﬂecting dis-
ease activity. Some composite indices may  include indirect markers
of inﬂammation, such as erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) [7], in addition to joint counts. Although
these indices are informative, routine clinical practice requires a
quantitative measure of disease activity that is rapid, reproducible
and easily performed.
Assays  to measure the concentration of proteins in the blood
ranging from cytokines to bone metabolites have been investi-
gated as a means to understand RA biology and to monitor disease
progression [8]. The vast majority of these studies use commer-
cially available enzyme-linked immunoassays. The clinical utility of
individual biomarkers has been limited as no single biomarker ade-
quately reﬂects disease activity or response to RA therapy [9–11].
By comparison, multiplex assays that measure the concentration of
multiple biomarkers simultaneously may  be better able to capture
Open access under CC BY-NC-ND license.the complexity of RA disease. Multiplex assays have been success-
fully developed in other complex disciplines such as oncology and
organ transplant rejection [12,13], suggesting that the develop-
ment of multiplex tests to aid in the evaluation and categorization
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Table  1
Sources of capture and detection antibodies and recombinant analyte.
Biomarker Sourcea
Capture antibodies Detection antibodies Analyte
EGF R&D Systems R&D Systems Peprotech
VEGF-A  Fitzgerald R&D Systems Peprotech
Leptin R&D  Systems Hytest Peprotech
IL-6 R&D  Systems R&D  Systems Peprotech
SAA Anogen  Anogen Peprotech
CRP  Hytest Hytest Hytest
VCAM-1  R&D Systems R&D Systems R&D Systems
MMP-1  R&D Systems R&D Systems Peprotech
MMP-3 R&D  Systems R&D  Systems R&D  Systems
TNF-R1 R&D  Systems R&D  Systems Peprotech
YKL-40 Quidel  Quidel R&D Systems
Resistin  Antigenix America R&D Systems Peprotech
untin
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f patients with RA should be possible. Indeed, there have been
ecent efforts to develop multiplex biomarker assays for RA [9].
owever, the analytical performance of these multiplex assays has
ot been fully evaluated [14].
The use of terms such as “validation” and how it applies
o various activities in the development and implementation of
iomarker assays is often confusing. In 2003, the validation and
mplementation of biochemical biomarker assays from preclini-
al discovery through clinical and post-marketing implementation
15] was addressed by the American Association of Pharmaceu-
ical Science/Clinical Ligand Assay Society Biomarkers Workshop
Salt Lake City, UT, USA, October 24–25, 2003). Emerging from
his workshop was the concept “Fit-for-Purpose” [16,17], wherein
he degree of validation required reﬂects the requirements of the
ntended use. Less extensive validation is required in the early
xploratory stages of biomarker selection, where many different
ssays for many different ligands, including singleplex and mul-
iplex arrays [9,10,18], may  be used to identify useful biomarker
ssays and eliminate uninformative assays. More extensive devel-
pment and validation, including certiﬁcation under the Clinical
aboratory Improvement Amendments (CLIA) of 1988, is needed
or assays to be used in clinical testing on human specimens for
iagnosis, prevention or treatment of any disease. While there are
o speciﬁc regulations on bioanalytical method validation, the Food
nd Drug Administration (FDA) and other agencies have devel-
ped guidelines for method validation. Valentin et al. [19] noted
hat despite publication of the recommendations for validation of
aboratory biomarker assays [15–17], few reports of validation of
iomarkers have been published since 2006. Often formal valida-
ion is substituted by comparison to other assays, which themselves
ay only be “For Research Use Only” with very limited sensitiv-
ty and/or reproducibility data, or correlation to a clinical outcome
9,20,21].
Because of the complexity of multiplex assays, their use in
linical trials or clinical laboratories requires extensive analytical
alidation in addition to clinical validation [22]. This is particu-
arly important for complex diseases such as RA in which multiple
iochemical pathways have been implicated [11]. Ideally, each
ndividual assay within a multiplex assay for RA should be eval-
ated for analytical performance, including sensitivity, precision,
nd parallelism [14]. In addition, the potential for cross-reactivity
nd sensitivity to interfering substances should be evaluated for
ach individual assay within a multiplex assay for RA. Finally,
he potential variability introduced by demographic diversity and
re-analytic specimen handling issues (i.e., specimen handling
nd storage conditions) should also be examined. The specimen
andling and storage conditions prior to analytical testing hasgton Station, NY, USA); Fitzgerald Ind. (Acton, MA, USA); Hytest (Turku, Finland);
 MN,  USA).
previously  been reported for this set of multiplexed sandwich
immunoassays and autoantibody assays for RA [23].
A  new multi-biomarker disease activity (MBDA) test to quantify
RA disease activity has been developed (VectraTMDA; Crescendo
BioscienceTM, South San Francisco, CA, USA). Initially, immunoas-
says for >100 biomarkers across multiple platforms, both multiplex
and individual ELISAs, were evaluated in a feasibility phase. Details
of the feasibility evaluation will be described elsewhere (Cavet,
personal communication). Biomarker assays emerging from the
feasibility evaluation were converted to a single, multiplex plat-
form. The performance of the multiplexed MSD assays used for
algorithm training and validation are described herein.
The  MBDA test uses Meso Scale Discovery (MSD, Gaithers-
burg, MD,  USA) sandwich immunoassay electrochemiluminescent
technology wherein capture antibodies are spotted on carbon elec-
trodes in a planar array and detection antibodies are labeled with
an electrochemiluminescent ruthenium reporter. Upon electrical
stimulation, light is produced from reporter molecules bound to
the electrode and identiﬁed through spatial addressing. The MBDA
test employs an algorithm based on measurement of 12 protein
biomarkers to provide a measure of disease activity for patients
with RA [24,25].
The  present study evaluated the analytical performance of each
of the individual biomarker assays that comprise the MBDA test
after they were converted to the MSD  platform. This work presents
the precision, parallelism, dynamic range, cross-reactivity, and
effect of interfering substances for the 12-biomarker assays in
the ﬁnal MBDA algorithm. Also presented is the application of
the MBDA test to a collection of RA patient samples represent-
ing a range of disease activity levels. The data indicate that the
biomarker assays and MBDA test scores are precise with mini-
mal cross-reactivity and interference. Evaluation of the individual
biomarkers in the RA patient samples conﬁrms previous literature
reports that RA is a complex disease involving multiple mark-
ers/pathways [11]. The integrated analysis of multiple biomarkers
may add value in the assessment of RA disease activity [24,25].
2.  Experimental
2.1. Materials
2.1.1. Assay reagents
Sources  for the analyte-speciﬁc capture and detection antibodypairs are presented in Table 1. All analytes were recombinant pro-
teins with the exception of CRP which was puriﬁed from human
sources. All other dilution and read buffers, with the exception of
wash buffer components, were from MSD  (Table 2). All dilution
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Table  2
Sources of diluents and buffers.
Buffers Sourcea Comments
Vendor Part Catalog no.
Panel A
Sample diluent MSD  Diluent 2 R51BB-2
Detection antibody diluent MSD Diluent 3 R51BA-6
Read buffer MSD Read Buffer T (4×) R92TC-1 Used at 2× in assay
Panel  B
Sample diluent MSD  Diluent 12 R50JA-3
Detection antibody diluent MSD  Diluent 12 R50JA-3
Read buffer MSD  Read Buffer T (4×) R92TC-1 Used at 1× in assay
Panel  C
Sample diluent MSD Diluent 2 R51BB-2
Detection antibody diluent MSD  Diluent 3 R51BA-6
Read buffer MSD  Read Buffer T (4×) R92TC-1 Used at 2× in assay
Wash  buffer EMD Millipore 10× PBS 6506 Used at 1×
GE  Healthcare Tween-20 17-1316-01 0.5% (v/v)
Sigma–Aldrich ProClin 46878-U 5 ppm
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Qa Source locations: Meso Scale Discovery (MSD, Bethesda, MD,  USA); EMD  Millip
O,  USA).
uffers contain MSD-proprietary reagents that address potential
erum interferants.
.1.2.  Multiplex standards
Prediluted,  multiplexed calibrator sets were prepared for each
anel. Each standard curve consisted of 8 points spanning the full
ange of the assay, including an assay blank. Prediluted standards
ere prepared with proteins spiked into the appropriate sam-
le diluent containing the equivalent serum concentration that is
resent in diluted samples to reﬂect the diluent/serum composi-
ion in the diluted patient samples: Panel A, Diluent 2 with 50%
etal bovine serum (FBS); Panel B, Diluent 12; Panel C, Diluent
 with 5% FBS. The equivalent serum content for Panel B (0.1%),
hich utilizes a 1:1000 dilution, is negligible and, therefore, is not
dded to the matrix during run control and standard manufacture.
BS was heat-inactivated and demonstrated to be negative in all
ssays. Prediluted standards were aliquoted into single-use vials
nd stored at −80 ◦C.
.1.3.  Assay quality controls
Serum  process controls were developed to monitor the entire
ssay process at both the biomarker level and the score level,
ncluding sample dilution. Large volume serum pools were
creened to establish ‘process controls’ with known biomarker
oncentrations and MBDA scores. These process controls were
liquoted into single-use vials, frozen and stored at −80 ◦C until
hawed for assay. Process controls contain the endogenous pro-
ein and are diluted alongside the samples for each assay run.
rocess control acceptability limits for the biomarkers were estab-
ished after analyzing the results of 16 replicates from multiple
ssays across multiple days (deﬁned by median ± 3 standard devia-
ions (SD)). One value (determined from the average of 2 duplicate
ells) for each of the 4 process controls is included on every plate.
he average observed biomarker concentrations of the run con-
rols and process controls (see Section 2.2.3.3) are presented in
upplementary Table 1. Following algorithm development, accep-
ance criteria for the MBDA score were established for the process
ontrols.
Prediluted, multiplexed quality control (QC) run control sets
ere developed to monitor the execution of each assay run from
ddition of the sample to the plate to data generation. Each run
ontrol set comprises two controls at concentrations designed to
bracket’ the range of concentrations observed in a collection of
12 RA subject samples from the InFoRM cohort (see Section 2.1.4).
C run controls sets were prepared using the respective sourceillerica, MA,  USA); GE Healthcare (Piscataway, NJ, USA); Sigma–Aldrich (St. Louis,
proteins  spiked into the appropriate sample diluent/serum mix-
ture (see Section 2.1.2). Prediluted run controls were aliquoted into
single-use vials and stored at −80 ◦C. Each run control was run
in duplicate on every plate and averaged for a single determina-
tion. Both QC run controls were required to fall within historical
biomarker concentration acceptability limits established after ana-
lyzing the results of >20 replicates from multiple assays across
multiple days (deﬁned by ±3 SD). If the observed biomarker con-
centrations of any QC run control fall outside of expected ranges,
indicating a problem with the execution of the assay for a speciﬁc
panel, the biomarker data is discarded and all samples on the failed
assay plate are repeated.
For  patient samples, the percent coefﬁcient of variation (% CV)
of the signals between the duplicate wells was  calculated for each
marker. If the % CV was above the biomarker-speciﬁc acceptability
limit (typically 20%), the concentration reported for that sample
was deemed unreliable and the sample was  retested.
2.1.4. Cohorts
Index for Rheumatoid Arthritis Measurement (InFoRM) is a
large, multicenter, observational study of the North American RA
population. Inclusion criteria were age >18 years with a diagno-
sis of RA made by a board-certiﬁed rheumatologist. All patients
satisﬁed the 1987 American College of Rheumatology criteria for
disease classiﬁcation [26] as part of the inclusion criteria. Patients
were recruited between April 2009 and March 2010 from 25 sites
in the United States and Canada. Patients concurrently enrolled
in a therapeutic drug clinical trial where the agent was unknown
(blinded) were excluded. All samples were collected under Investi-
gational Review Board approved protocols with informed consent.
The analyses in this study included the ﬁrst 512 subjects enrolled.
Demographically, 389 were female, 123 were male; median age
was 60 years (range 20–91); disease duration median was 11
years (range <1–64 years); the disease activity score 28 using CRP
(DAS28-CRP) [7] median was 3.23 (range 1.07–8.24); 390 subjects
were rheumatoid factor (RF) positive; 295 subjects were using bio-
logical therapies.
2.2.  Methods
2.2.1. Assay protocol
Assays  for 12 biomarkers were evaluated, including epidermal
growth factor (EGF), vascular endothelial growth factor A (VEGF-A),
leptin, interleukin 6 (IL-6), serum amyloid A (SAA), CRP, vascu-
lar cell adhesion molecule 1 (VCAM-1), matrix metalloproteinase
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 (MMP-1), matrix metalloproteinase 3 (MMP-3), tumor necrosis
actor receptor superfamily member 1A (TNF-RI), human cartilage
lycoprotein 39 (YKL-40), and resistin. Multispot 96-well plates
MSD) were spotted in speciﬁc locations with biomarker-speciﬁc
apture antibodies. Biomarker concentrations were determined
sing 3 separate multiplex panels, based on sample dilution
equirements. Panels A (EGF, IL-6, leptin, and VEGF-A) and C (MMP-
, MMP-3, resistin, TNF-RI, and YKL-40) utilized a 7-spot-per-well
ormat, while Panel B (CRP, SAA, and VCAM-1) utilized a 4-spot-
er-well format. All assays were performed at controlled ambient
emperature of 20 ± 5 ◦C. Prediluted standards and QC run controls
ere loaded onto the plate alongside diluted patient samples and
iluted process controls.
All  diluted serum samples and process controls were prepared
sing a validated Hamilton STAR (Reno, NV, USA) automated dilu-
ion platform. Dilutions for Panels A, B, and C were 1:2, 1:1000, and
:20, respectively, in the sample diluents indicated in Table 2.
50 L (for Panels A and C) and 25 L (for Panel B) of standard,
lank, or sample were added to the appropriate duplicate wells of
he 96-well plate. The plates were incubated for 120 min  with con-
inuous shaking at 750 rpm and then washed 3 times in wash buffer
phosphate buffered saline + 0.05% Tween-20 + 5 ppm Proclin as a
reservative). Twenty-ﬁve L of prediluted blends of detection
ntibodies was added to each well. Antibodies were conjugated to
ULFO-TAG per the vendor’s protocol (MSD).
Following incubation of a blend of the appropriate detection
ntibodies for 60 min  with continuous shaking at 750 rpm, plates
ere washed 3 times in wash buffer, and 150 L of Read Buffer T
as loaded in each well. Plates were then immediately read on the
ector Imager 6000.
.2.2.  Data acquisition and analysis
Data acquisition used the Discovery Workbench software for
imultaneous quantiﬁcation of analytes in multiplex formats using
lectrochemiluminescence detection [27]. Discovery Workbench
oftware calculates the four-parameter logistic regression curve ﬁts
28] for each standard curve and interpolates concentrations for all
amples and controls. Data were exported into Microsoft Excel and
 (www.r-project.org) for further analysis.
.2.3. Assay characteristics
.2.3.1.  Dynamic range. To establish the assay’s dynamic range
or each biomarker, the limit of quantitation (LOQ), deﬁned as
he actual amount of analyte that can be reliably detected in a
ample and at which the total analytical error meets the require-
ents for accuracy and precision, was determined as described in
P17-A Clinical Laboratory Standards Institute (CLSI). For the pur-
ose of this analysis, acceptable accuracy at the LOQ was  deﬁned
s 80–120% recovery of the input mass based on the vendors
peciﬁcation for the speciﬁc protein, and the acceptable precision
equirement at the LOQ was deﬁned as a 20% CV. An assay’s ana-
ytical measurable range was deﬁned as the difference between
he upper limit (ULOQ) and the lower limit (LLOQ). The clini-
ally reportable or dynamic range for an assay was deﬁned as the
ilution-adjusted range. LLOQ and ULOQ were determined by eval-
ation of multiple measurements of each biomarker concentration
n a panel of 8 control samples at both the ULOQ and LLOQ over 2
ots with approximately 20 plates/lot over a minimum of 10 days.
.2.3.2. Parallelism. Parallelism was established by analysis of
wofold serial dilutions of 6 different clinical samples for each panel
n the appropriate sample diluent (Table 2). For Panels B and C, 2
ilutions above and below the selected dilution factor, the mini-
um required dilution (MRD), were evaluated: Panel B, 250-, 500-,
000-, 2000- and 4000-fold dilutions in Diluent 12; Panel C, 5-, 10-,
0-, 40- and 80-fold dilutions in Diluent 2. For Panel A, which is ad Biomedical Analysis 70 (2012) 415– 424
recommended twofold dilution, neat, 2-, 4-, 8- and 16-fold dilutions
in Diluent 2 were performed. Concentrations of the biomarkers in
each sample/dilution was determined and adjusted for the dilution
factor. The % recovery was  determined relative to the MRD. The %
CV was  determined for the indicated test dilution and the MRD
combined.
2.2.3.3. Biomarker precision. Intra-assay precision for the biomark-
ers was determined with 14 replicates of 4 different serum pools
per plate with 2 replicate plates from 2 different lots for a total of
4 plates. In all experiments, each assay plate contained a standard
curve, process controls samples, and high and low run controls in
duplicate.
Biomarker inter-assay precision, or run to run precision, was
determined across 2 lots of plates/reagents with approximately 20
plates per lot, performed over 10 days; 2 plates from 2 lots were run
by a single operator each day with 3–4 different operators running
assays across the 10 days. Four serum pools were diluted and ana-
lyzed with the prediluted high and low QC run controls (see Section
2.1.3) on each plate.
2.2.3.4.  Precision of the MBDA score. For intra-run precision of the
MBDA score, 4 serum pools were each run 14 times on a single
plate. Two plates from each of 2 different lots were evaluated, and
the means and % CVs for the MBDA score were calculated.
For run-to-run precision, samples from 28 InFoRM subjects with
a range of disease activity (MBDA scores, 12–80; DAS28-CRP scores,
1.3–8.0) were selected based on the DAS28-CRP score and analyzed
for the MBDA score in 10 different runs.
2.2.3.5. Interference.
2.2.3.5.1. Rheumatoid factor and human anti-mouse antibody
interference. Evaluation of RF or HAMA interference was  per-
formed with individual patient samples. RF and HAMA were tested
individually. The serum samples used had established RF or HAMA
concentrations as determined by testing at Crescendo Bioscience
(RF, Cobas, Roche, Indianapolis, IN, USA) or speciﬁed by the sup-
plier (HAMA, Bioreclamation Inc., NY, USA). Samples with high
RF or HAMA values were mixed with samples with low/no RF or
HAMA values in equal ratios (e.g., 50% high RF serum and 50% low
RF serum) and subsequently diluted at the assay’s intended dilu-
tion. Each of the original samples with high RF or HAMA values and
low/no RF or HAMA levels were also run on the plate to establish
the baseline expected biomarker concentrations. Percent recovery
was calculated for the observed mixture concentration versus the
expected concentration. The acceptance criterion to demonstrate
that RF or HAMA did not interfere with an individual biomarker
assay was  an average recovery of 80–120% of the expected values
for the mixed samples. MBDA scores calculated from the predicted
concentrations of the mixtures were compared to the MBDA scores
observed from the mixtures.
2.2.3.5.2. Biological interference. Studies were performed to
establish the level of interference observed in hemolytic, icteric,
and lipemic samples. Serum pools were spiked at 2 targeted lev-
els of the interfering substances and compared with the same pool
without the interfering substance to determine the level of interfer-
ence in both the individual biomarker assays comprising the MBDA
test and the score of the MBDA algorithm. Interfering substances
consisted of hemoglobin (Sigma–Aldrich, St. Louis, MO,  USA), biliru-
bin (Sigma–Aldrich, St. Louis, MO,  USA) and liposyn (Hospira, Lake
Forest, IL, USA). Spikes and spike controls were created consistently
by the addition of minimum volumes of interferant or interferant
diluent in order to reduce the risk of matrix effects or experi-
mental artifacts. For each spike, at all levels tested, the interferant
was added to the serum pool at a ratio of 10% interferant to 90%
serum. Comparisons made with samples not having the interfering
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ubstance were performed by preparing a “spike control,” in which
 sample was prepared with 10% of the appropriate diluent with-
ut interferant to 90% serum. Test concentrations were selected
o match or exceed the levels listed in EP07-A2 CLSI Standard.
he percent recovery in the observed concentration for each indi-
idual biomarker between a sample spiked with the interfering
ubstance and the corresponding spiked control sample was cal-
ulated. The acceptance criterion to demonstrate that a potentially
nterfering substance did not interfere (at the levels tested) with
 biomarker assay was a median recovery across the four serum
ools of 80–120% of the expected values for the spiked samples.
he acceptance criterion to demonstrate that a potentially inter-
ering substance did not interfere (at the levels tested) with the
BDA score was a difference in MBDA score of 95–105% for each
piked serum pool relative to the corresponding spike control.
2.2.3.5.3.  Drug interference. The level of interference for drugs
ommonly administered to RA patients was characterized for the
uantitative biomarker immunoassays. Serum samples (consisting
f individual patient samples or pools) with a range of biomarker
oncentrations were spiked with a targeted level of a potentially
nterfering drug, and the observed biomarker concentrations were
etermined. These concentrations were selected based on either
ata listed in Appendix C of CLSI/NCCLS EP07-A2, peak-level phar-
acokinetic data, or the package insert. For drugs, concentrations
qual to twice the Cmax were employed. Percent recovery in the
bserved concentration for each individual biomarker between
 sample spiked with the interfering substance and the corre-
ponding nonspiked sample was calculated. The average percent
ecovery across all the serum samples for each biomarker for each
rug/interferant was calculated. The deﬁned tolerance limits for
rug interference with a biomarker assay was deﬁned as an aver-
ge recovery of 80–120%. The acceptance criterion to demonstrate
hat a drug did not interfere with the MBDA score was a difference
n MBDA score of 95–105% for each spiked serum pool relative to
he corresponding spike control.
2.2.3.5.4. Cross-reactivity. Cross-reactivity was  assessed by
esting each biomarker protein individually at its ULOQ. The detec-
ion antibodies included reagents for every biomarker in the
anel. Cross-reactivity was deﬁned as the observed concentra-
ion of each individual biomarker, determined in the absence of
hat particular biomarker but in the presence of a potentially
ross-reacting biomarker. The apparent concentration resulting
rom the cross-reacting species was compared to the input
oncentration of the cross-reacting protein to determine the %
ross-reactivity for all possible combinations within a multiplex
anel. For cross-reactivity across panels, a blend of panel-speciﬁc
ecombinant/puriﬁed proteins was used.
2.2.3.5.5. Freeze–thaw stability. Evaluation of freeze–thaw sta-
ility was performed using 4 prospectively obtained serum samples
ith varying biomarker concentrations and 4 serum pools/process
ontrols. Upon receipt of the processed serum, individual aliquots
ere prepared for each of the three freeze–thaw cycles. A fresh
unfrozen) aliquot was prepared and placed in a 4 ◦C refrigera-
or. Freezing was performed in −80 ◦C freezers for a minimum of
0 min. Each thaw was then performed at ambient temperature
on the bench-top). Once samples were completely thawed, they
ere mixed thoroughly prior to refreezing or undergoing dilution
or the assay. Serum pools had been previously prepared, aliquoted
nd frozen, so previously unfrozen baseline aliquots were not avail-
ble, therefore, the data from the initial thaw was used to compare
ubsequent freeze–thaw cycles. Aliquots from earlier freeze–thaw
ycles remained at −80 ◦C until all aliquots were ready for assay.
ll of the freeze–thaw aliquots from an individual, including the
resh sample, were assayed within the same plate. Two replicate
lates containing all samples from the study were performed for
ach assay on the same day the samples were received. Percentd Biomedical Analysis 70 (2012) 415– 424 419
differences  were calculated between the biomarker concentrations
of each successive freeze–thaw cycle relative to the fresh samples.
Vectra DA scores were calculated using the obtained biomarker
concentrations for each freeze–thaw cycle and compared to the
Vectra DA score of the fresh sample. The acceptance criterion
for sample freeze–thaw stability was  a median percent difference
≤15% of the concentration obtained on the fresh sample.
3.  Calculations
3.1. Calculation of the MBDA score
The MBDA algorithm was developed in a separate series of stud-
ies and clinically validated in an independent cohort using the
DAS28-CRP as a gold standard. Derivation and clinical validation
of this algorithm are reported separately [24,25]. The MBDA  algo-
rithm was  developed by analyzing biomarker assays performed on
samples from several observational studies.
PTJC = Prediction of Tender Joint Count = −26.72+3.243 ×
[YKL-40]1/10 − 11.97 × [EGF]1/10 + 15.72 × [IL-6]1/10 + 0.4594 ×
[Leptin]1/10 + 3.881 × [SAA]1/10 + 0.7388 × [TNF-RI]1/10 − 0.2557 ×
[VCAM-1]1/10 + 0.7003 × [VEGF-A]1/10
PSJC = Prediction of Swollen Joint Count = −26.63 + 3.232 ×
[YKL-40]1/10 − 11.93 × [EGF]1/10 + 15.67 × [IL-6]1/10 + 0.4578 ×
[Leptin]1/10 + 3.868 × [SAA]1/10 + 0.7363 × [TNF-RI]1/10 − 0.2548 ×
[VCAM-1]1/10 + 0.6979 × [VEGF-A]1/10
PPGS = Prediction of Patient Global Score = –13.489 + 5.474 ×
[IL-6]1/10 + 0.486 × [SAA]1/10 + 2.246 × [MMP-1]1/10 + 1.684 ×
[Leptin]1/10 + 4.14 × [TNF-RI]1/10 + 2.292 × [VEGF-A]1/10 − 1.898 ×
[EGF]1/10 + 0.028 × [MMP-3]1/10 − 2.892 × [VCAM-1]1/10 − 0.506 ×
[Resistin]1/10
MBDA score = round(max(min((0.56 × sqrt(max(PTJC,0)) +
0.28 × sqrt(max(PSJC,0)) + 0.14 × PPGS + 0.36 × log(CRP/106 + 1)) ×
10.53 + 1, 100),1))
The biomarker concentrations used in these formulas are
expressed in pg/mL. All concentration values except that of CRP
were transformed to the power 1/10 prior to use in the algorithm.
This results in more normally distributed values, similar to a log-
transformation.
MBDA scores are integers from 1 to 100, with disease activity
thresholds designed to be equivalent to thresholds from DAS28-
CRP. MBDA scores ≤29 are considered low disease activity; MBDA
scores of 30 to ≤44 are considered moderate disease activity; MBDA
scores >45 are considered high disease activity.
4. Results and discussion
4.1.  Assay calibration curves
Speciﬁc  capture and detection antibody pairs were tested for
LOD, LOQ, quantiﬁcation, cross-reactivity, and intra- and inter-
assay variation. All recombinant protein–antibody combinations
tested were evaluated individually before incorporation into the
multiplex assay.
The  calibration curves for each RA biomarker showed dynamic
ranges covering 3.3–4.2 orders of magnitude (Fig. 1), with LLOQs
such that the biomarkers could be measured at low concentrations
(Table 3). Despite differences of >8 logs in concentration of the
biomarkers, the range of patient sample concentrations (5–95th
percentile) was engineered to fall within the ULOQ and LLOQ for
each of the biomarkers. This was  accomplished by grouping assays
into 3 panels based on analyte concentration ranges and selecting
appropriate assay dilutions needed to adequately quantitate the
biomarker. Of the 6144 biomarker concentration determinations
for the InFoRM 512 patients, only 29 determinations were outside
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Table  3
Characteristics of MBDA biomarker assays.
Biomarker Dilution LOD
(pg/mL)
LLOQ
(pg/mL)
ULOQ
(pg/mL)
InFoRM  512 samples Intra-assay
variation
(% CV)
Inter-assay
variation
(%  CV)
5th percentile
(pg/mL)
Median
concentration
(pg/mL)
95th  percentile
(pg/mL)
EGF 2 0.64 0.64 10,000 40 150 340 5.3 9
IL-6  2 1.3 1.3 20,000 2.7 10 76.8 6.6 10.7
Leptin  2 92 185 120,000 3000 23,000 92,000 7.1 9.4
VEGF-A  2 2.4 2.4 10,000 98 250 680 5.9 8.9
CRP 1000 5400 5400 250,000,000 400,000 4,300,000 43,700,000 6.2 6.5
SAA 1000 16,000 16,000 250,000,000 840,000 3,710,000 52,600,000 8.1 15.7
VCAM-1  1000 24,000 24,000 50,000,000 390,000 580,000 940,000 7 8.1
MMP-1  20 640 640 2,000,000 3500 9500 29,000 18.8 17.6
MMP-3  20 130 130 2,000,000 10,600 27,000 103,000 7 7.5
 
 
 
o
e
q
4
i
m
l
n
S
m
e
p
t
p
t
d
T
s
c
o
f
(
t
F
v
f
rResistin  20 3.2 8 25,000 4000
TNF-R1  20 31 62 64,000 1230
YKL-40  20 21 64 1,000,000 29,000
f the limits of quantiﬁcation, 17 of which were leptin values which
xceeded the ULOQ. In these situations, the corresponding limit of
uantiﬁcation was imputed.
.2.  Parallelism
Parallelism is critical for the performance of quantitative
mmunoassays,  particularly if the readout is done spectrophoto-
etrically, for example, and the dynamic range of the assay is
imited. If a sample falls out of the linear range of the assay, it would
ecessitate a repeat assay with a different dilution of the sample.
hould the native analyte not perform dilutionally as the synthetic
olecule used in the standards, the assay may  not be linear and an
rroneous result may  occur.
Parallelism  was determined by twofold serial dilutions in the
anel-speciﬁc dilution buffer with 2 dilutions above and 2 dilu-
ions below the determined dilution factor, or MRD, with 6 different
atient samples for each panel. For Panel A, in which the MRD  is
wofold, the ﬁrst dilution is neat. The average % recovery at each
ilution relative to the MRD  and the % CV are presented in Table 4.
he average % CV was calculated based on the concentration of the
amples at the test dilution and the MRD  for the panel. All con-
entrations tested were acceptable for Panel C. For Panel A, the
bserved concentrations of the neat samples were underestimated
or all biomarkers, an indication of the “hook” effect. For Panel B
MRD, 1:1000), both SAA and CRP over-recovered at the 1:250 dilu-
ion; VCAM-1, however, was linear at all dilutions. These results
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ig. 1. Calibration curves for individual biomarkers in MBDA test. Concentration
alues  for each standard curve have been adjusted to account for the dilution factor
or each panel member. Blue lines represent Panel A; green lines represent Panel B;
ed lines represent Panel C. ECU, electrochemical units.7400 16,700 8.4 7.8
1950 3630 7.4 6.9
82,000 354,000 7.7 10.5
show that the MSD  platform provides sufﬁcient dynamic range for
all biomarkers within a panel such that additional dilution of the
sample and repeat assays are not necessary.
4.3. Biomarker precision
Precision  is an important, often overlooked, parameter in the
analytical performance of an assay. If the concentration range of a
biomarker in a patient population is small relative to the variability
of the assay, it will not be possible to detect signiﬁcant differences
in the level of that biomarker.
Intra-assay  precision was evaluated with 14 replicates of 4
serum pools with 2 replicate plates from 2 lots of plates/reagents.
Means of the % CV for pooled serum samples tested for intra-assay
precision are presented in Table 3. Mean % CVs for intra-assay vari-
ation ranged from 5.3 to 18.8.
Inter-assay precision determinations were performed on each
panel using 2 lots of plates/reagents per day with the QC run con-
trols and 4 serum pools. Over the course of 10 days, 3–4 different
operators ran assays depending on the panel. Mean CV for the
4 serum pools for inter-assay variation ranged from 6.5 to 17.6
(Table 3). These values, therefore, incorporate variance from both
lot, operator and day, and represent the performance that would
be expected day to day.
4.4.  MBDA score precision
The  average intra-assay precision of the MBDA score for the 4
serum pools was 1.1% (range, 0.9–1.2%) across 4 plates (2 plates
from each of 2 lots of plates/reagents). Inter-run precision was
determined by testing 28 InFoRM samples, selected on the basis of
a range of DAS28 scores (MBDA scores, 12–80; DAS28-CRP scores,
1.3–8.0), over 10 days. The median CV was  1.6% (range, 0–6.4%).
The inter-run precision of the MBDA score in 28 InFoRM patients is
presented in Fig. 2.
Inspection  of the data in Table 3 reveals that for all analytes of
the MBDA test, the inter-assay variation (day to day) is such that
differences in biomarkers will be apparent within the patient pop-
ulation (5–95 percentile of the InFoRM 512). Similarly, the MBDA
score is highly reproducible across the disease spectrum and suf-
ﬁcient to allow discrimination of changes in the MBDA score over
time. Furthermore, as the inter-assay precision determinations in
Table 3 were performed over 10 days, with 20 plates from each
of 2 lots with a minimum of 3 different operators, the individual
biomarkers in the multiplexed assays showed good precision across
time, operators, and reagent lots.
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Table  4
Parallelism of MBDA biomarker assays.
Panel Biomarker Dilutiona
Neat 2 4 8 16
A EGF 22b (95)c 100 (0) 100 (4) 99 (6) 97 (7)
IL-6  14 (108) 100 (0) 111 (9) 120 (13) 123 (18)
Leptin 37 (68) 100 (0) 106 (6) 117 (11) 121 (13)
VEGF-A 55 (41) 100 (0) 103 (4) 105 (4) 107 (5)
250 500 1000 2000 4000
B CRP 215 (48) 148 (27) 100 (0) 76 (22) 69 (29)
SAA  105 (34) 113 (18) 100 (0) 77 (18) 65 (30)
VCAM-1  97 (9) 102 (5) 100 (0) 105 (8) 108 (8)
5 10 20 40 80
C MMP-1 91 (13) 101 (7) 100 (0) 104 (5) 96 (7)
MMP-3 103 (5) 99 (3) 100 (0) 96 (3) 97 (6)
Resistin  89 (12) 104 (5) 100 (0) 97 (5) 97 (4)
TNF-R1  129 (17) 113 (8) 100 (0) 97 (4) 95 (5)
YKL-40 95 (9) 105 (5) 100 (0) 95 (4) 92 (6)
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b Average percent recovery relative to minimum required dilution.
c Average % CV for all samples at the indicated test dilution and the minimum req
.5. Interference studies
The  need for consistency in conditions for a multiplex assay
resents a particular challenge for assays involving proteins. In
nﬂammatory diseases, numerous endogenous serum proteins
uch as heterophilic antibodies (e.g., RF), soluble receptors, com-
lement, immune complexes, lysozyme, collectins (lectins), and
cute phase proteins can interfere with immunoassays [29]. Drugs
hat are commonly prescribed for treatment of patients repre-
ent another potential source of interference. In particular, certain
iologics have an immunoglobulin component which could inter-
ct with the capture and/or detection antibodies in the multiplex
ssays. Potential sources of interference were evaluated for indi-
idual biomarkers as well as the MBDA score.
.5.1. RF and HAMA interference
Interference  due to RF or HAMA was evaluated by mixing
amples of known RF and HAMA. Within the range of RF IgA
–867 U/mL, RF IgG 4–112 U/mL, and RF IgM 3–2368 IU/mL in the
nmixed samples, the average recovery for each biomarker in the
ixtures was between 92% and 102% based on the individual sam-
le concentrations (Supplementary Table 2). Within the range of
ndetectable (<5) to 38 ng/mL HAMA in the unmixed samples, the
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ig. 2. Reproducibility of MBDA score. Twenty-eight clinical samples representing
 range of disease activity were assayed on 10 different days and the MBDA score
alculated. All 10 MBDA scores for each sample are represented. Individual data
oints are represented by black diamonds; red bars denote mean values. dilution.
average recovery for each biomarker was between 89% and 111%.
The observed and expected MBDA scores for both RF and HAMA
mixtures were highly correlated, R2 >0.99 and 0.96, respectively.
These results demonstrate that interference by serum RF and HAMA
in biomarker assays of the MBDA test was  minimal and had no
impact on the MBDA score.
4.5.2.  Hemolytic, icteric or lipemic samples
Interference due to hemolytic, icteric or lipemic samples was
evaluated. The median percent recovery for individual biomark-
ers and for the MBDA score when serum samples were spiked
with common endogenous interfering substances is presented in
Supplementary Table 3. Median recovery was  between 82% and
120% for all biomarkers, indicating that hemoglobin, bilirubin, and
lipids (at the levels tested) did not interfere with the individual
biomarker assays. Similarly, the percent recovery of the MBDA
score was  between 98% and 103%, demonstrating that hemoglobin,
bilirubin, and lipids (at the levels tested) did not interfere with the
MBDA score. These results show that interference due to hemol-
ysis, icterus or lipemia was minimal on the biomarker assays and
had no impact on the MBDA score.
4.5.3. Drug interference
The  presence of certain RA drugs in serum could potentially
interfere with the detection of individual biomarkers. The aver-
age percent recovery for the individual biomarkers when serum
samples were spiked with drugs that are commonly prescribed for
patients with RA, including disease-modifying antirheumatic drugs
(DMARDs), analgesics, non-steroidal anti-inﬂammatory drugs,
steroids and biologics, is presented in Supplementary Table 4. The
mean recovery for all biomarkers in the presence of drugs was
82%–120%. No change in the MBDA score was  observed for the
drugs tested within the acceptance criteria (range 96% to 105% of
unspiked sample), indicating that interference was minimal.
4.6.  Cross-reactivity studies
Antibodies  validated for singleplex assays may  be unsuitable
for use in a multiplex assay because they may  exhibit cross-
reactivity or interference with other components in a multiplex
format that may  not be detected in a singleplex. Cross-reactivity
among biomarkers and detection antibodies can be particularly
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Table  5
Cross-reactivity of biomarkers and capture antibodies.
Analyte panels Capture antibody panelsa
Panel A Panel B Panel C
EGF IL-6 Leptin VEGF-A CRP SAA VCAM-1 MMP-1 MMP-3 Resistin TNF-R1 YKL-40
Panel A
EGF  5,000 <LoD 111(2.22) <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD
IL-6  7(0.07) 10,000 346(3.46) <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD
Leptin <LoD <LoD 120,000 <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD
VEGF-A 8(0.16) <LoD 185(3.7) 5,000 <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD
Panel  B
CRP  6(0.00) <LoD <LoD <LoD 250,000 304(0.12) <LoD <LoD <LoD <LoD <LoD <LoD
SAA  6(0.00) <LoD <LoD <LoD 936(0.37) 250,000 822(0.33) <LoD <LoD <LoD <LoD <LoD
VCAM-1  6(0.01) <LoD <LoD <LoD <LoD 235(0.24) 100,000 <LoD <LoD <LoD <LoD <LoD
Panel  C
MMP-1 <LoD <LoD <LoD <LoD <LoD <LoD <LoD 100,000 56(0.00) <LoD <LoD <LoD
MMP-3 <LoD <LoD <LoD <LoD <LoD <LoD <LoD <LoD 100,000 <LoD <LoD <LoD
Resistin  <LoD <LoD <LoD <LoD <LoD <LoD <LoD 27(1.08) 15(0.06) 2,500 <LoD <LoD
TNF-R1  <LoD <LoD <LoD <LoD <LoD <LoD <LoD 47(1.47) <LoD <LoD 3,200 <LoD
YKL-40 <LoD <LoD <LoD <LoD <LoD <LoD <LoD 140(0.28) 41(0.08) 33(0.07) 16(0.03) 50,000
ross-
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roblematic when trying to match antibody pairs from different
ssays into a multiplex format and ﬁnd an optimum for all assays.
Cross-reactivity was not observed in 112 of 132 combinations
Table 5). The maximum cross-reactivity observed was on the lep-
in capture, 3.7%, with 185 pg/mL of leptin observed in the presence
f 5000 pg/mL VEGF-A input into the well (in the absence of lep-
in). IL-6 and EGF showed similar cross-reactivities. The inputs at
he ULOQ used for these proteins were 7-, 130- and 15-fold higher
han the 95th percentile of the InFoRM 512 sample concentra-
ion distribution. Therefore, cross-reactivity was only observed at
nput biomarker concentrations that exceed physiologic concen-
rations (compare InFoRM 512 Samples, 95th percentile, pg/mL
ersus ULOQ, pg/mL in Table 3), suggesting that the chance of cross-
eactivity in patient samples is negligible.
.7. Freeze–thaw stability
Stability  to 3 cycles of freeze–thaw was evaluated with 4 fresh
linical samples and 4 serum pools. Process controls used for QC
urposes did not undergo multiple freeze–thaw cycles. Up to 3
reeze–thaw cycles had no impact on the concentration of the
iomarkers (range −8 to +6 average % Recovery, see Supplementary
VCAM-1 0.9 0.6 0.9 1.0 0.7 1.0 0.9 0.9 1.1 1.0 1.1 1.9 1.8 0.8
EGF 1.1 2.5 1.8 1.2 1.1 1.7 0.6 1.8 0.9 1.8 0.9 0.4 0.3 1.5
VEGF-A 0.8 1.5 1.5 2.0 1.3 2.1 0.5 1.4 0.5 1.4 3.1 2.3 1.5 1.8
IL-6 0.2 0.2 0.4 0.5 0.3 0.3 0.5 2.6 0.8 0.9 1.2 1.9 0.9 2.0
TNFR1 0.6 0.8 0.6 0.6 0.6 1.0 0.7 1.0 0.9 1.1 0.8 1.4 1.5 1.1
MMP-1 0.2 0.5 0.2 0.3 0.9 0.7 1.0 0.5 0.7 0.4 0.6 0.7 0.7 3.4
MMP-3 0.9 4.6 0.6 0.6 0.5 2.8 0.5 0.9 0.7 0.8 0.8 0.8 1.0 1.6
YKL-40 0.3 0.6 0.7 0.5 0.7 0.9 0.3 0.8 1.1 1.2 1.5 1.1 1.9 1.5
Leptin 0.3 0.1 0.2 0.4 0.8 0.4 1.1 0.1 1.0 1.9 0.6 1.6 0.1 5.0
Resistin 0.5 0.9 0.5 0.3 0.8 2.0 1.4 0.8 0.4 1.2 1.0 1.6 1.6 2.2
SAA 0.2 0.2 0.2 0.1 0.2 0.5 0.4 0.3 0.8 1.8 1.6 0.8 1.0 4.9
CRP 0.0 0.1 0.1 0.2 0.1 0.4 0.1 1.4 0.6 0.7 1.5 1.0 3.8 3.4
MBDA 12 14 14 15 16 18 24 36 37 39 46 46 49 57
ig. 3. Heat map  of patient disease activity scores compared with individual biomarker co
ample divided by the median concentration of the InFoRM 512 patients for each indiv
 concentration that is 10-times greater than the median concentration. Colors are bas
oncentration is represented as yellow. Increase in blue intensity corresponds to incre
ntensity corresponds to decreasing values below the median concentration for the m
resented at the bottom of the ﬁgure.reactivity. <LoD = less than limit of detection.
Table  5) for the fresh samples as well as the serum pools. As would
be expected with no change in the biomarker concentrations within
the reproducibility of the assays, no change in the MBDA score was
observed in samples or sample pools upon initial freezing or with
multiple freeze–thaw cycles (Supplementary Table 6).
4.8.  The MBDA score and biomarker levels in clinical samples
The  contribution of individual biomarkers to the MBDA score
was evaluated in the 28 RA patients investigated in the precision
experiments which represent a large range of DAS28-CRP scores.
Because the concentration ranges of the biomarker assays are so dif-
ferent (Fig. 1 and Table 3), the concentration ranges across biomark-
ers were normalized by calculating the ratio of the measured
concentration relative to the median concentration of the 512
InFoRM subjects for each biomarker. Fig. 3 shows a heat map  of
the 28 RA patients (selected for a range of disease activity, see
Section 2.2.3.4) with their associated individual biomarkers and
MBDA score. Biomarker concentrations at the low disease activ-
ity (see Section 3.1) are well below the median concentration for
each biomarker with the exception of EGF, which is inversely cor-
related to disease activity. Biomarker concentrations are much
 2.1 0.9 1.2 1.1 0.9 1.0 1.6 1.3 1.2 1.0 1.3 1.2 1.3 1.2
 0.2 0.7 0.9 1.0 1.0 1.7 1.1 1.5 0.3 1.3 0.5 1.0 0.4 0.3
 1.7 2.2 2.3 2.0 2.6 1.8 4.9 3.4 2.2 2.1 0.9 3.6 1.9 2.3
 2.6 1.4 2.6 3.5 5.6 8.7 15 7.0 14 2.2 4.8 5.5 57 12
 5.4 1.1 1.6 1.3 1.6 1.5 6.7 1.8 1.2 1.6 1.4 1.5 1.9 1.0
 1.8 1.0 2.0 1.8 0.1 4.3 0.7 1.1 1.4 3.1 0.7 1.1 0.9 3.5
 1.5 1.5 1.7 1.4 1.3 3.4 8.5 8.2 4.6 12 2.1 9.0 2.9 21
 5.7 2.5 5.0 3.8 0.9 2.4 5.8 2.0 1.3 4.4 0.9 2.9 2.6 1.9
 3.8 0.3 3.6 2.5 1.5 0.2 6.6 0.5 1.7 1.6 0.3 0.8 0.2 0.3
 4.0 1.6 1.0 2.5 1.6 1.9 2.5 0.8 1.6 1.2 1.6 0.8 0.9 0.8
 1.2 12 3.8 8.5 50 18 10 35 28 52 55 57 8.2 42
 0.8 9.5 6.3 7.8 4.6 13 3.3 22 5.5 34 45 25 6.4 33
57 61 62 65 67 70 71 73 74 74 75 75 75 80
ncentrations. Values in the heat map represent the concentration in the individual
idual marker. Therefore, the median is a value of 1 and a value of 10 represents
ed on concentration range and median on an individual biomarker basis. Median
asing values above the median concentration for the marker and increase in red
arker. Samples are represented in columns. The MBDA score for each sample is
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loser to the median concentration in the subjects with moder-
te disease activity. With high disease activity, the majority of
iomarkers are above the median concentration. With increasing
isease activity, biomarker concentrations are often as much as 10-
o 50-fold greater than the median, however, no single biomarker
as a monotonic relationship with the MBDA score because the
core is calculated using a combination of all the biomarker
oncentrations.
. Conclusions
The 12 individual biomarkers comprising the MBDA tests
nitially were selected as the result of a multi-step algorithm
evelopment process, which involved 6 major studies of the rela-
ionships between 130 different candidate biomarkers and clinical
isease activity measures. A set of 25 candidate biomarker assays
hat came out of a feasibility evaluation were selected for further
evelopment. The assays employed during the feasibility evalua-
ion were from several different platforms, such as Luminex and
tandard ELISA formats, and were from several different research
se only kits, some of which may  demonstrate great variability lot
o lot. In order to make the most reproducible assays, lot to lot, run
o run, these assays were developed on a single platform. In order
o conserve sample volume and reduce costs, these assays were
eveloped on a multiplex platform.
The development of multiplex assays presents unique chal-
enges not encountered with singleplex assays. The optimal
onditions for one assay frequently are not the same conditions that
re optimal for another. When combined in a multiplex format, it is
ritical that conditions are determined that allow optimal perfor-
ance for all assays. In developing the MBDA test, all optimizations
ere performed as multivariate ANOVA with special attention to
esponse surface methodology. This approach allowed for the selec-
ion of conditions (signal, background, signal to background, etc.)
hat were optimal for all members of a panel.
The results of this study demonstrate that the 12 individual
iomarker assays comprising the MBDA test exhibit a high level
f precision with minimal cross-reactivity and interference by
ubstances commonly seen in RA patients. Moreover, the het-
rogeneity of biomarker patterns observed among RA patients is
onsistent with earlier studies indicating that RA is a complex dis-
ase involving multiple pathways and may  provide novel insights
nto the molecular pathophysiology of RA disease activity. Mul-
iplex assays with high performance enable the development of
ulti-biomarker diagnostic tests that may  deliver more personal-
zed medicine.
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